The Korean journal of internal medicine · 2013
Neuroprotective effects of Vitis vinifera extract on prediabetic mice induced by a high-fat diet.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jin Heung Yong, Cha Youn Soo, Baek Hong Sun, Park Tae Sun
Аннотация
BACKGROUND/AIMS: Vitis vinifera grape seed extract (VVE) contains oligomeric proanthocyanidins that show antioxidant and free radical-scavenging activities. We evaluated VVE for its neuroprotective effect in prediabetic mice induce by a high-fat diet (HD).
METHODS: Mice were divided into four groups according to VVE dose: those fed a normal diet (ND; n = 10), HD (n = 10), HD with 100 mg/kg VVE (n = 10), and HD with 250 mg/kg VVE (n = 10). After 12 weeks, immunohistochemical analyses were carried out using a polyclonal antibody against antiprotein gene product 9.5 (protein-gene-product, 9.5), and intraepidermal innervation was subsequently quantified as nerve fiber abundance per unit length of epidermis (intraepidermal nerve fiber, IENF/mm).
RESULTS: Daily administration of VVE at doses of 100 or 250 mg/kg for 12 weeks protected HD mice from nerve fiber loss compared to untreated mice, as follows (IENF/mm): controls (40.95 ± 5.40), HD (28.70 ± 6.37), HD with 100 mg/kg (41.14 ± 1.12), and HD with 250 mg/kg (48.98 ± 7.01; p < 0.05, HD with VVE vs. HD).
CONCLUSIONS: This study provides scientific support for the therapeutic potential of VVE in peripheral neuropathy in an HD mouse model. Our results suggest that VVE could play a role in the management of peripheral neuropathy, similar to other antioxidants known to be beneficial for diabetic peripheral neuropathy.
METHODS: Mice were divided into four groups according to VVE dose: those fed a normal diet (ND; n = 10), HD (n = 10), HD with 100 mg/kg VVE (n = 10), and HD with 250 mg/kg VVE (n = 10). After 12 weeks, immunohistochemical analyses were carried out using a polyclonal antibody against antiprotein gene product 9.5 (protein-gene-product, 9.5), and intraepidermal innervation was subsequently quantified as nerve fiber abundance per unit length of epidermis (intraepidermal nerve fiber, IENF/mm).
RESULTS: Daily administration of VVE at doses of 100 or 250 mg/kg for 12 weeks protected HD mice from nerve fiber loss compared to untreated mice, as follows (IENF/mm): controls (40.95 ± 5.40), HD (28.70 ± 6.37), HD with 100 mg/kg (41.14 ± 1.12), and HD with 250 mg/kg (48.98 ± 7.01; p < 0.05, HD with VVE vs. HD).
CONCLUSIONS: This study provides scientific support for the therapeutic potential of VVE in peripheral neuropathy in an HD mouse model. Our results suggest that VVE could play a role in the management of peripheral neuropathy, similar to other antioxidants known to be beneficial for diabetic peripheral neuropathy.
Предметные рубрики MeSH
AnimalsAntioxidantsBiomarkersBlood GlucoseBody WeightDiabetic NeuropathiesDiet, High-FatDisease Models, AnimalDose-Response Relationship, DrugEpidermisGrape Seed ExtractLipidsMaleMiceMice, Inbred C57BLNeuroprotective AgentsPeripheral NervesPhytotherapyPlants, MedicinalPrediabetic StateTime FactorsVitis